- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
Patent holdings for IPC class A61K 31/712
Total number of patents in this class: 1719
10-year publication summary
90
|
101
|
104
|
121
|
157
|
147
|
154
|
196
|
158
|
60
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Ionis Pharmaceuticals, Inc. | 859 |
121 |
Alnylam Pharmaceuticals, Inc. | 1146 |
44 |
F. Hoffmann-La Roche AG | 7926 |
31 |
Hoffmann-La Roche Inc. | 3379 |
30 |
Nippon Shinyaku Co., Ltd. | 329 |
26 |
Osaka University | 3362 |
26 |
Wave Life Sciences Ltd. | 164 |
25 |
Sarepta Therapeutics, Inc. | 377 |
24 |
University of Massachusetts | 2218 |
23 |
Roche Innovation Center Copenhagen A/S | 134 |
22 |
Avidity Biosciences, Inc. | 145 |
21 |
Isis Pharmaceuticals, Inc. | 216 |
17 |
Arrowhead Pharmaceuticals, Inc. | 292 |
15 |
National Center of Neurology and Psychiatry | 149 |
15 |
The Regents of the University of California | 19812 |
14 |
Centre National de La Recherche Scientifique | 10321 |
14 |
CuRNA, Inc. | 131 |
13 |
Replicor Inc. | 25 |
13 |
Sirnaomics, Inc. | 111 |
13 |
Dyne Therapeutics, Inc. | 238 |
13 |
Other owners | 1199 |